Illumina, Inc. (ILMN) company profile
Close on Nov 17, 2026Market cap $30.63BP/E 34.8Yield –
About Illumina
Laboratory Analytical Instruments, SIC 3826
Illumina, Inc. develops and provides genetic analysis solutions, focusing on sequencing- and microarray-based technologies. The company supplies integrated platforms, specialized instruments, and consumable reagents that enable researchers and healthcare specialists to analyze genetic variation and biological function. Its offerings support a broad range of life science applications, including clinical diagnostics, oncology, reproductive health, and genomics research. Customers primarily include academic and research institutions, clinical laboratories, pharmaceutical and biotechnology companies, and genomic centers.
The company operates globally across several major geographic regions, including the Americas, Europe, China, and the Asia-Pacific, Middle East, and Africa regions. In addition to its domestic presence in the United States, it conducts international business and maintains accounts and operations in jurisdictions such as Singapore and the United Kingdom. Illumina maintains its principal executive headquarters in San Diego, California.
Summary of the business section of Illumina's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Illumina, Inc.
- Founded
- 1998
- Headquarters
- San Diego, CA
- Address
- 5200 Illumina Way 92122
- Phone
- (858) 202-4500
- Website
- www.illumina.com
- Employees
- 52, Dec 31, 2023
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- January 3
- Auditor
- Ernst & Young LLP, SanDiego, California
Stock & identifiers
- Ticker
- ILMN
- Exchange
- Nasdaq
- IPO date
- Jul 28, 2000
- Shares outstanding
- 151M, Oct 23, 2026
- Public float
- $9.20B, Jun 29, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Sep 23, 2008
- SEC CIK
- 1110803
- CUSIP
- 452327109
- ISIN
- US4523271090
- FIGI
- BBG000DSMS70
- Share class FIGI
- BBG001SF4NY1
- LEI
- SQ95QG8SR5Q56LSNF682
- EIN
- 33-0804655
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jacob Thaysen | Chief Executive Officer, Director | 107,770 |
| Scott D. Ericksen | VP, Chief Accounting Officer | 14,029 |
| Patricia Leckman | SVP, Chief People Officer | 21,120 |
| Kevin Carl Pegels | Chief of Global Operations | 28,434 |
| Steven Barnard | SVP, Chief Technology Officer | 40,567 |
| Julie Ann Coletti | Chief Legal Officer | 18,763 |
| Christensen Jakob Wedel | SVP, Strategy/Corp Development | 14,023 |
| Michael C. Sullivan | Chief Commercial Officer | 4,503 |
| Scott M. Davies | Chief Legal Officer | 20,338 |
| Ankur Dhingra | SVP, Chief Financial Officer | 34,264 |
| Everett Cunningham | SVP, Chief Commercial Officer | 46,592 |
| Carissa Rollins | SVP, Chief Information Officer | 18,447 |
| Keith A. Meister | Director | 215,713 |
| Scott B. Ullem | Director | 11,143 |
| Daniel Skovronsky | Director | 1,674 |
| Caroline Dorsa | Director | 15,754 |
| Scott Gottlieb | Director | 14,795 |
| Philip W. Schiller | Director | 22,220 |
| David P. King | Director | 2,072 |
| Anna Richo | Director | 8,527 |
| Susan E. Siegel | Director | 20,541 |
| Robert S. Epstein | Director | 22,139 |
| Frances Arnold | Director | 20,907 |
| Gary S. Guthart | Director | 16,430 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Charles Dadswell | $0 | $0 | $3.71M | $36 | $122 |
| FY2025 Francis Desouza | $0 | $0 | $3.71M | $36 | $122 |
| FY2025 Jacob Thaysen | $11.02M | $12.83M | $3.71M | $36 | $122 |
| FY2024 Charles Dadswell | $0 | $0 | $5.43M | $37 | $92 |
| FY2024 Francis Desouza | $0 | $0 | $5.43M | $37 | $92 |
| FY2024 Jacob Thaysen | $14.80M | $17.69M | $5.43M | $37 | $92 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Jacob Thaysen Chief Executive Officer | $1.00M | – | $8.76M | $1.16M | $100.77K | $11.02M | -26% |
| Ankur Dhingra Chief Financial Officer | $650.00K | – | $3.09M | $325.33K | $10.67K | $4.08M | -30% |
| Steve Barnard Chief Technology Officer | $600.00K | – | $2.56M | $300.30K | $17.68K | $3.48M | -13% |
| Kevin Pegels Chief of Global Operations | $575.00K | – | $2.30M | $287.79K | $20.20K | $3.18M | -17% |
| Everett Cunningham Former Chief Commercial Officer | $650.00K | $500.00K | $2.87M | – | $65.88K | $4.09M | -59% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“The modifications affected 52 employees with units granted in 2019, which resulted in total incremental share-based compensation cost of approximately $ 41 million, and 72 employees with units granted in 2020, which resulted in total incremental share-based compensation cost of approximately $ 65 million.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?